LEADER 01493nam  2200373Ia 450 
001 9910697093403321
005 20230902161549.0
035   $a(CKB)5470000002383964
035   $a(OCoLC)587585389
035   $a(EXLCZ)995470000002383964
100   $a20100330d1997      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eSUPAC-MR : modified release solid oral dosage forms : scale-up and postapproval changes, chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[1997]
215   $a1 electronic resource (ii, 36, 6, 6 pages)
300   $a"CMC 8."
300   $a"September 1997."
320   $aIncludes bibliographical references (page 36).
517   $aGuidance for industry 
606   $aSolid dosage forms$zUnited States$xTesting
606   $aDrugs$xTherapeutic equivalency$xDocumentation$zUnited States
615  0$aSolid dosage forms$xTesting.
615  0$aDrugs$xTherapeutic equivalency$xDocumentation
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910697093403321
996   $aGuidance for industry$93434577
997   $aUNINA